ERBB4 and breast cancer: Furthermore, silencing of miR-141 enhanced ERBB4 expression, which plays a critical role in trastuzumab resistance in breast cancer cells; taken together, these results indicate that both miR-141 as well as its target, ERBB4, may be potential tools for the efficient treatment of trastuzumab-resistant breast cancers [176].